The federal government's most consequential cannabis proceeding in decades officially opened June 29 at DEA headquarters in Arlington, Virginia - and the first day was almost entirely procedural. No dramatic testimony. No early signals about where the agency might land. Just an administrative law judge methodically laying the groundwork for what is scheduled to run through July 15. That may disappoint observers hoping for immediate fireworks, but for cannabis operators, compliance professionals, and investors watching this process, the proceedings themselves are what matter most right now.

The hearing is designed to determine whether marijuana should be moved from Schedule I to Schedule III under the federal Controlled Substances Act - a shift that would not legalize cannabis nationally but would carry substantial downstream consequences for how the industry operates. State-licensed operators in markets with sophisticated regulatory frameworks, including operators using Illinois seed-to-sale dispensary software to manage compliance, inventory, and reporting obligations, have long built their businesses around a patchwork of state rules precisely because federal law offered nothing workable. A Schedule III designation would begin to change that calculation, though the full implications would take years to sort out through Congress, federal agencies, and the courts.

This hearing replaces an earlier rescheduling attempt that stalled in early 2025 amid legal disputes and procedural complications before testimony could be completed. The Department of Justice moved this spring to withdraw that proceeding and replace it with the expedited format now underway. The restart matters: it signals that the current administration has enough institutional interest to push the process forward rather than let it quietly expire in procedural limbo.

What Schedule III Actually Means for Cannabis Businesses

Here's the part operators should focus on. The most immediate and concrete business implication of a Schedule III reclassification would be relief from Internal Revenue Code Section 280E. Under current federal law, businesses trafficking in Schedule I or II controlled substances cannot deduct ordinary business expenses - payroll, rent, marketing, utilities - from their federal taxable income. For dispensaries, that creates effective tax rates that can dramatically exceed what comparable retail businesses pay. Moving marijuana to Schedule III would remove it from 280E's scope entirely, which would represent a meaningful shift in unit economics for virtually every licensed cannabis retailer in the country.

Research barriers would also ease. Schedule I classification restricts the conditions under which scientists can study cannabis, limiting the volume and quality of clinical research that can be conducted in the United States. Schedule III allows considerably more flexibility, which could accelerate the kind of peer-reviewed evidence base that both supports product development and informs state-level consumer safety regulations. That matters to operators because consumer safety frameworks - lab testing requirements, certificate of analysis standards, potency disclosure rules - are increasingly shaped by available science. Better research infrastructure tends to produce more consistent compliance expectations over time.

Who Is Testifying and What the Hearing Is Actually Examining

The administrative proceeding is not a courtroom trial, and that distinction matters. An administrative law judge is overseeing structured presentations of factual evidence from a range of participants: government representatives, medical researchers, industry organizations, attorneys, and other stakeholders that the DEA selected to participate. The hearing is open to the public in limited capacity, and the DEA has committed to publishing an official transcript once testimony concludes.

Witnesses over the coming days are expected to address marijuana's accepted medical use, its abuse potential, relevant scientific research, and the broader policy implications of changing the federal classification. Supporters of rescheduling are expected to argue that the current Schedule I designation - which holds that a substance has no accepted medical use and a high potential for abuse - no longer reflects the scientific record, particularly given that dozens of states now operate regulated medical cannabis markets. Opponents are expected to raise concerns about public health, youth access, and addiction, though many of the arguments historically deployed against rescheduling have struggled to hold up against accumulated research and state-market experience. The DEA has not signaled a timeline for issuing its final ruling following the hearings.

Why Multi-State Operators and Investors Are Watching Closely

For multi-state operators managing compliance across multiple license jurisdictions, a federal rescheduling decision would not eliminate state-level regulatory complexity. Seed-to-sale tracking, packaging and labeling compliance, excise tax obligations, and local licensing requirements are all creatures of state and municipal law - they exist independently of the CSA classification and would continue regardless of what happens in Arlington. What rescheduling could change is the cost structure that underlies the entire business model, particularly through 280E relief.

Investors, for their part, have priced in a range of rescheduling outcomes for some time. The practical effect on cannabis equity valuations will depend heavily on how quickly any 280E relief translates into improved cash flow and whether Congress takes additional steps - such as the SAFE Banking Act or broader legalization legislation - in response to whatever the DEA ultimately decides. A Schedule III ruling alone does not open bank lending or normalize payment processing for cannabis retailers; those remain banking-regulation problems that rescheduling does not solve directly.

The first day accomplished what first days in administrative proceedings are supposed to accomplish: establishing order, clarifying process, and getting the machinery moving. The substance arrives in the days ahead. For an industry that has operated under federal prohibition for more than five decades, even an orderly procedural opening is something the cannabis business has never had before.